Evidence map›Paper›PMID 42097144›Full record

Trial reportCell reports. Medicine2026

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

David A Braun, Marcus S Noel, Ryan H Moy, Kurt Demel, Martin Gutierrez, Sunil Sharma, Arif Hussain, Shirish Gadgeel, Julio Peguero, Toni K Choueiri and 9 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

David A BraunYale School of Medicine, New Haven, CT, USA. Electronic address: david.braun@yale.edu.
Marcus S NoelGeorgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Ryan H MoyColumbia University Irving Medical Center, New York, NY, USA.
Kurt DemelHealthPartners, St. Louis Park, MN, USA.
Martin GutierrezHackensack University Medical Center - John Theurer Cancer Center, Hackensack, NJ, USA.
Sunil SharmaHonor Health Research Institute, Scottsdale, AZ, USA.
Arif HussainUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Shirish GadgeelHenry Ford Cancer Institute, Henry Ford Health Center, Detroit, MI, USA.
Julio PegueroOncology Consultants, Houston, TX, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Hamid EmamekhooUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Brian Van TineDepartment of Medicine, Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Rama BalaramanFlorida Cancer Affiliates-US Oncology, Ocala, FL, USA.
GiNell ElliottNimbus Therapeutics, Boston, MA, USA.
Sritama NathNimbus Therapeutics, Boston, MA, USA.
Scott R DaigleNimbus Therapeutics, Boston, MA, USA.
Pavan KumarNimbus Therapeutics, Boston, MA, USA.
Anita ScheuberNimbus Therapeutics, Boston, MA, USA. Electronic address: anita.scheuber@nimbustx.com.
David SommerhalderNEXT Oncology, San Antonio, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic progenitor kinase 1 (HPK1) induces potent anti-tumor immunity in preclinical models by activating and recruiting T cells, B cells, and dendritic cells into the tumor microenvironment (TME). Here, we evaluate NDI-101150, a potent, selective HPK1 inhibitor, in a phase 1/2 trial as a monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The monotherapy maximum tolerated dose (MTD) is 150 mg once daily, and doses tested up to 100 mg once daily are combinable with pembrolizumab without reaching an MTD. In clear cell renal cell carcinoma, the investigator-assessed overall response rate with monotherapy treatment is 13.6%, including one complete response and two partial responses, with a clinical benefit rate of 27.3% and a disease control rate of 54.5%. Pharmacodynamic analyses show pharmacodynamic biomarker phospho-SLP76 inhibition and increased activated CD8

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsProtein Kinase InhibitorsProtein Serine-Threonine KinasesAdultAgedCarcinoma, Renal CellDendritic CellsFemaleHumansMaleMaximum Tolerated DoseMiddle AgedTumor MicroenvironmentAntibodies, Monoclonal, Humanizedhematopoietic progenitor kinase 1pembrolizumabProtein Kinase InhibitorsProtein Serine-Threonine Kinasescancer immunologycytotoxic CD8 T cellsHPK1immune regulationimmunotherapyrenal cell carcinoma

Identifiers

PMID42097144
PMCPMC13198303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.